REG - Indivior PLC - Notice of Results

IndiviorAnnouncement

01/02/2022 09:25

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220201:nRSA3008Aa&default-theme=true

RNS Number : 3008A  Indivior PLC  01 February 2022

 

 

 

Indivior to Announce FY 2021 Results and Host a Presentation on February
16(th)

Slough, UK, and Richmond, VA, February 1, 2022 - Indivior PLC (LON: INDV)
today announced that it will release its FY 2021 results on February 16(th) at
7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available
via the London Stock Exchange's Regulatory News Service (RNS) and on the
"Investors" section of the company's website at www.indivior.com
(http://www.indivior.com) .

Mark Crossley, Chief Executive Officer, and other members of Indivior's
leadership team will host a presentation  via live webcast at 13:00 GMT (8:00
a.m. U.S. Eastern) on February 16(th).

Access to the Live Webcast Presentation

The webcast event and materials can be accessed on the "Investors" section of
the company's website at www.indivior.com (http://www.indivior.com) before the
event begins.

The webcast link is: https://edge.media-server.com/mmc/p/8tao6fad
(https://edge.media-server.com/mmc/p/8tao6fad)

Participants may access the presentation telephonically:

·    US participants 1-646-741-3167

·    International participants +44 (0) 2071-928338

 

Please reference confirmation ID 8268632. A replay of the presentation will be
available at www.indivior.com (http://www.indivior.com) .

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat addiction and serious mental illnesses.
Our vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of addiction. Indivior is dedicated to transforming addiction from a global
human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has
a pipeline of product candidates designed to both expand on its heritage in
this category and potentially address other chronic conditions and
co-occurring disorders of addiction, including alcohol use disorder.
Headquartered in the United States in Richmond, VA, Indivior employs more than
700 individuals globally and its portfolio of products is available in over 40
countries worldwide. Visit www.indivior.com (http://www.indivior.com)
(http://www.indivior.com/) to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior
(http://www.linkedin.com/company/indivior) .
(http://www.linkedin.com/company/indivior)

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREANAFEAEAEEA